TABLE I.

Studies included in the analysis

Reference	ClinicalTrials.gov ID	Study drug	Dose	Patients (n)	Newcastle–Ottawa scale
Anti–PD-1 trials
Sharma et al., 201623	NCT01928394	Nivolumab	3 mg/kg IV every 2 weeks	86	5
Balar et al., 201724	NCT02335424	Pembrolizumab	200 mg every 3 weeks	370	6
Plimack et al., 201710	NCT01848834	Pembrolizumab	10 mg/kg IV every 2 weeks	33	6
Sharma et al., 201725	NCT02387996	Nivolumab	3 mg/kg, 1-hour IV infusion every 2 weeks	270	6
Anti–PD-L1 trials
Balar et al., 201722	NCT02108652a	Atezolizumab	1200 mg IV every 3 weeks	119	6
Perez-Gracia et al., 201726, Rosenberg et al., 201621	NCT02108652a	Atezolizumab	1200 mg IV every 3 weeks	310	6
Powles et al., 201727	NCT01693562	Durvalumab	10 mg/kg every 2 weeks	191	6
Pal et al., 201828	NCT02589717	Atezolizumab	200 mg IV every 3 weeks	214	3
Patel et al., 201829	NCT01772004	Avelumab	10 mg/kg every 2 weeks	249	6
Petrylak et al., 201830	NCT01375842	Atezolizumab	15 mg/kg every 3 weeks	95	5

^aThis study had 2 cohorts: first-line and second-line. The study reporting the most recent or complete data was used for the analysis.

IV = intravenously.